Learn More
Invitrogen™ IL-1 beta Polyclonal Antibody
Goat Polyclonal Antibody
Supplier: Invitrogen™ PA547533
Description
In direct ELISAs, approximately 40% cross-reactivity with recombinant feline IL-1 beta is observed, less than 10% cross-reactivity with recombinant human IL-1 beta, recombinant rhesus macaque IL-1 beta, recombinant equine IL-1 beta, and recombinant porcine IL-1 beta is observed, less than 5% cross-reactivity with recombinant mouse (rm) IL-1 beta, recombinant rat IL-1 beta, and recombinant cotton rat (rcr) IL-1 beta is observed, and less than 1% cross-reactivity with rcrIL-1 alpha, rmIL-1ra, and recombinant canine IL-18 is observed. Reconstitute at 0.2 mg/mL in sterile PBS. Endoxin level is <0.10 EU per 1 μg of the antibody by the LAL method.
Interleukin-1 beta (IL-1 beta) is a proinflammatory cytokine expressed by monocytes, macrophages, and dendritic cells. IL-1 beta is synthesized in response to inflammatory stimuli as a 31 kDa inactive pro-form that accumulates in the cytosol. Cleavage of pro-IL-1 beta into the active 17 kDa protein requires the activation of inflammasomes, which are multi-protein complexes that respond to pathogens, stress conditions, and other danger signals. Inflammasome activation triggers the processing of the caspase-1 precursor into its active form, which in turn cleaves pro-IL-1 beta. IL-1 beta lacks a signal sequence peptide for classical ER/Golgi pathway and is secreted alongside caspase-1 via an alternate and incompletely understood mechanism. Although IL-1 beta is most often secreted in its active form, secretion of the uncleaved protein may be detectable under some biological conditions. IL-1 beta signals through two receptors, IL-1RI and IL-1RII, both of which are shared with IL-1 alpha. IL-1 beta activity can be moderated by IL-1 Receptor Antagonist (IL-1RA), a protein produced by many cell types that blocks receptor binding through competitive inhibition. IL-1 beta play an important role in innate host defense by triggering the production of other proinflammatory cytokines in target cells and initiating acute-phase responses to infection and injury. Elevated levels of IL-1 beta have been associated with many chronic inflammatory conditions IL-1 beta neutralizing antibodies potential therapeutic value.
Specifications
IL-1 beta | |
Polyclonal | |
Unconjugated | |
IL1B | |
catabolin; cytokine; Hematopoietin 1 (H1); IFN beta inducing factor; il 1b; IL 1β; IL-1; IL1 B; IL-1 beta; IL-1 precursor; IL1B; IL-1B; IL1B1; IL1beta; IL-1beta; IL1-BETA; IL1F2; IL1β; ILN; Interleukin; interleukin 1 beta; Interleukin 1 beta precursor; interleukin 1, beta; interleukin 1, beta 1; interleukin 1-beta; interleukin*1*beta; Interleukin1 beta; interleukin-1 beta; interleukin-1 beta precursor; interleukin-1 beta precursor (AA -113 to 153); interleukin-1 beta proprotein; interleukin-1b; interleukin-1beta; interleukin-beta; LAF; lymphocyte proliferation-potentiating factor; Osteoclast activating factor (OAF); preinterleukin 1 beta; Pro interleukin 1 beta; prointerleukin-1 beta; pro-interleukin-1-beta | |
Goat | |
Antigen affinity chromatography | |
RUO | |
403974 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Lyophilized |
Flow Cytometry, Neutralization, Western Blot | |
0.2 mg/mL | |
PBS with 5% trehalose and No Preservative | |
Q28292 | |
IL1B | |
E. coli-derived recombinant canine IL-1 beta/IL-1F2 Ala114-Ser265. | |
100 μg | |
Primary | |
Canine | |
Antibody | |
IgG |
Safety and Handling
Your input is important to us. Please complete this form to provide feedback related to the content on this product.